Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows

Inclusion Criteria: 1. Male or female subjects who are 18 years of age or older (subjects should have an interest in the effacement of glabellar rhytides) with or without previous botulinum Toxin Type A exposure; 2. In good physical and mental health as determined by the investigator based on medical history, physical examination, and/or clinical laboratory tests; 3. Noticeable presence of the glabellar rhytides for a period of 6 months or longer; 4. Score at least a 2 (moderate severity) at baseline screening on the investigator's and subject's assessments (reference photographs provided) at forced frown; and 5. Capable of understanding and complying with the protocol and must have signed the informed consent document prior to performance of any study-related procedures. Exclusion Criteria: 1. History of psychiatric problems that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes; 2. History of autoimmune disease, that, in the opinion of the investigator, might interfere with subject outcomes (e.g., osteoarthritis is not considered an exclusion criteria; however, subjects with dermatomyositis are not permitted to participate in this study); 3. History or presence of clinically significant cardiovascular, respiratory, hepatic/biliary, renal, gastrointestinal, endocrinological, or neurological disorders constituting a possible risk factor that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes; 4. Inability to substantially efface glabellar lines by manually spreading skin apart; 5. Eyelid ptosis; 6. Myasthenia gravis (from medical history or diseases of neurotransmission); 7. Current history of facial nerve paralysis; 8. Concurrent dermatologic disease of the face in the glabellar area that is deemed by the investigator to make the subject an inappropriate candidate for the study; 9. Recent flu-like syndrome that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes; 10. Neuromuscular disorder that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes; 11. Active multisystems disease that, in the investigator's opinion, might influence the outcome measures or the safety of the subject; 12. Has any condition(s) that in the investigator's opinion would a) warrant exclusion from the study, or b) prevent the subject from completing the study; 13. Currently receiving aminoglycoside antibiotic therapy, curare-like drugs, quinidine, succinylcholine, polymyxins, anticholinesterases, magnesium sulfate, or lincosamides; 14. Has taken any investigational drug during the 30 days prior to screening visit; 15. Have had Botulinum Toxin treatments to the glabellar and/or forehead area during the 6 months prior to screening visit; 16. Have had dermal filler treatment to glabellar area during the 6 months prior to screening visit; 17. Female subjects who are pregnant or lactating. (Female subjects of childbearing potential must have negative urine pregnancy test results prior to enrollment into the study. Such subjects, including peri-menopausal women who have had a menstrual period within one year, must use appropriate birth control (see protocol/informed consent for description) 18. Unwilling or unable to comply with the protocol or to cooperate fully with the investigator and site personnel; and 19. Unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent document is available.